Highlights
- Zero Candida Ltd commenced trading on the TSX Venture Exchange.
- The company develops AI-powered medical devices for vulvovaginal candidiasis (VVC).
- Its blue light technology offers a non-chemical treatment approach with real-time monitoring.
The health technology sector welcomed Zero Candida Ltd (TSXV:ZCT), an Israeli femtech company, to the TSX Venture Exchange. The firm focuses on solutions for women's health, specifically vulvovaginal candidiasis (VVC), a condition affecting a significant portion of the global female population.
Innovative Device for Women's Health
Zero Candida has developed an AI-driven medical device resembling a tampon. This device uses controlled blue light technology to eradicate Candida fungus effectively. The treatment is reportedly capable of achieving a high efficacy rate in a single overnight session. Its non-chemical approach minimizes side effects and aims to reduce recurrence rates.
The device also incorporates Wi-Fi-enabled data transmission, allowing gynecologists to monitor and personalize treatments remotely. This feature broadens accessibility, particularly for underserved populations in developing regions.
Steps Toward Clinical Application
The company has announced plans to finalize a human-use prototype by early 2025. Preclinical studies are scheduled for completion later that year, paving the way for potential regulatory submissions. Zero Candida's listing on the exchange facilitates access to resources necessary for these developmental milestones.
Business Combination Agreement
The listing was achieved through a three-cornered amalgamation with a Canadian reporting issuer. This resulted in the issuance of new shares, consolidating the company’s structure and providing a robust foundation for its future endeavors.